United States - English - NLM (National Library of Medicine)

remedyrepack inc. - diltiazem hydrochloride (unii: olh94387te) (diltiazem - unii:ee92bbp03h) - diltiazem hydrochloride 60 mg - diltiazem hydrochloride tablets are indicated for the management of chronic stable angina and angina due to coronary artery spasm. diltiazem hydrochloride tablets are contraindicated in: - patients with sick sinus syndrome except in the presence of a functioning ventricular pacemaker - patients with second – or third-degree av block except in the presence of a functioning ventricular pacemaker - patients with hypotension (less than 90 mm hg systolic) - patients who have demonstrated hypersensitivity to the drug - patients which acute myocardial infarction and pulmonary congestion documents by x-ray on admission

Ireland - English - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd t/a gerard laboratories - ivabradine oxalate - film coated tablet - 5 milligram - ivabradine

Ireland - English - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd t/a gerard laboratories - ivabradine oxalate - film coated tablet - 7.5 milligram - ivabradine

Malta - English - Medicines Authority

teva b.v. swensweg 5, 2031 ga haarlem, netherlands - ivabradine adipate - film-coated tablet - ivabradine adipate 5 mg - cardiac therapy

Malta - English - Medicines Authority

teva b.v. swensweg 5, 2031 ga haarlem, netherlands - ivabradine adipate - film-coated tablet - ivabradine adipate 7.5 mg - cardiac therapy

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - ivabradine - film-coated tablet - 7.5 milligram(s) - other cardiac preparations; ivabradine

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - ivabradine - film-coated tablet - 5 milligram(s) - other cardiac preparations; ivabradine

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - ivabradine hydrochloride (unii: tp19837bzk) (ivabradine - unii:3h48l0lpzq) - corlanor is indicated to reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with left ventricular ejection fraction ≤ 35%, who are in sinus rhythm with resting heart rate ≥ 70 beats per minute and either are on maximally tolerated doses of beta-blockers or have a contraindication to beta-blocker use.  corlanor is indicated for the treatment of stable symptomatic heart failure due to dilated cardiomyopathy (dcm) in pediatric patients aged 6 months and older, who are in sinus rhythm with an elevated heart rate. corlanor is contraindicated in patients with: • acute decompensated heart failure • clinically significant hypotension • sick sinus syndrome, sinoatrial block or 3 rd degree av block, unless a functioning demand pacemaker is present • clinically significant bradycardia  [see warnings and precautions ( 5.3 )] • severe hepatic impairment  [see use in specific populations ( 8.6 )] • pacemaker

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

teva uk ltd - ivabradine hydrochloride - tablet - 5mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

teva uk ltd - ivabradine hydrochloride - tablet - 7.5mg